Adverse reactions and treatment measures of advanced solid tumors treated with antibody-drug conjugates

VernacularTitle:抗体药物偶联物治疗晚期实体瘤的不良反应和处理措施
Author: Jingdan PANG ¹ ; Yingying DU ; Jie DA
Author Information

1. 安徽医科大学第一附属医院肿瘤内科，合肥　230000
Keywords: Antibody-drug conjugate; Adverse reactions; Occurrence mechanism; Treatment measures
From: Journal of International Oncology 2022;49(4):220-224
CountryChina
Language:Chinese
Abstract: Novel antibody-drug conjugates (ADCs) are a hot spot in the research and development of new drugs for advanced solid tumors. ADCs have achieved significant efficacy in the treatment of advanced breast cancer, urothelial carcinoma, gastric cancer and other solid tumors, but their adverse reactions such as ocular toxicity, pulmonary toxicity, hematological toxicity, and liver toxicity cannot be ignored, and it is crucial to effectively deal with the adverse reactions of ADCs.